{"id":"W4295807681","doi":"10.1016/j.jaad.2022.08.061","title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial","year":2022,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":279,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research","funders":"Cilag; LEO Pharma; Eli Lilly and Company; Bristol-Myers Squibb; Galderma; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Biogen; Celgene; Amgen; Pfizer","keywords":"Apremilast; Medicine; Psoriasis; Placebo; Adverse effect; Psoriasis Area and Severity Index; Internal medicine; Randomized controlled trial; Gastroenterology; Dermatology Life Quality Index; Clinical trial; Dermatology; Psoriatic arthritis; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002298352,0.0002574859,0.001354405,0.0002261281,0.0002497244,0.00001282971,0.0004291002,0.0001817319,0.00003539994],"category_scores_gemma":[0.0008024819,0.000168442,0.0002688458,0.000319146,0.0005586058,0.00009557917,0.0001976672,0.0005569015,8.374008e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008444149,"about_ca_system_score_gemma":0.0002206686,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006119365,"about_ca_topic_score_gemma":0.00003682646,"domain_scores_codex":[0.9949381,0.002819093,0.001422789,0.0003128954,0.0001998313,0.0003072316],"domain_scores_gemma":[0.9932207,0.004296341,0.002109956,0.0001919991,0.0001305497,0.00005049665],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9543763,0.0005435612,0.00007830486,0.00001221168,0.001214545,0.000002133156,0.001742104,0.000303163,0.003047328,0.0000644193,0.001178012,0.0374379],"study_design_scores_gemma":[0.9729749,0.001646093,0.0005669021,0.00005502451,0.001470404,0.0003668653,0.001492474,0.0001453072,0.01713491,0.0002666411,0.003697729,0.0001827711],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9880842,0.001817923,0.00001861958,0.005185552,0.0008834715,0.003352296,0.0006018615,0.000008297433,0.00004776351],"genre_scores_gemma":[0.9986908,0.000261157,0.0003592542,0.0001738122,0.0001305505,0.0003087683,0.00003533513,0.00001882641,0.00002145844],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03725513,"threshold_uncertainty_score":0.6868865,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05161720070112816,"score_gpt":0.3402775865708558,"score_spread":0.2886603858697276,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}